Continual reassessment method for ordered groups

DOI10.1111/1541-0420.00050MaRDI QIDQ3079132zbMATH OpenOpenAlexWikidataFDO

Authors John O'Quigley, Xavier Paoletti

Publication date 1 March 2011

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/1541-0420.00050

zbMATH Keywords

clinical trialscontinual reassessment methoddose-finding studiesmaximum tolerated doseordered groupspharmacologyphase I designstoxicitytwo-sample problem

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
• Individualized dosing for multiple ordered groups of patients
• Continual reassessment method for partial ordering
• Continual reassessment and related dose-finding designs
• On the consistency of the continual reassessment method with multiple toxicity constraints

Cites work

• Consistency of continual reassessment method under model misspecification
• Continual Reassessment Method: A Likelihood Approach
• Miscellanea. A stopping rule for the continual reassessment method
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

Cited in

(23)

• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
• Individualized dosing for multiple ordered groups of patients
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Adaptive clinical trial designs for phase I cancer studies
• Theoretical study of the continual reassessment method
• A note on continual reassessment method
• A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• Risk-group-specific dose finding based on an average toxicity score
• Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
• Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
• Patient-specific dose finding in phase I clinical trials
• Two‐Dimensional Dose Finding in Discrete Dose Space
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Subgroup-specific dose finding for phase I-II trials using Bayesian clustering
• Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers
• A product of independent beta probabilities dose escalation design for dual-agent phase I trials
• A design for phase I trials in completely or partially ordered groups
• Designs for phase I trials in ordered groups
• On inclusion of covariates in model based dose finding clinical trial designs
• Dose individualization for phase I cancer trials with broadened eligibility
• Continual reassessment and related dose-finding designs

This page was built for publication: Continual reassessment method for ordered groups

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3079132)